| pubmed-article:15126112 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15126112 | lifeskim:mentions | umls-concept:C0083867 | lld:lifeskim |
| pubmed-article:15126112 | lifeskim:mentions | umls-concept:C0085196 | lld:lifeskim |
| pubmed-article:15126112 | lifeskim:mentions | umls-concept:C0221198 | lld:lifeskim |
| pubmed-article:15126112 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15126112 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:15126112 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:15126112 | pubmed:dateCreated | 2004-5-5 | lld:pubmed |
| pubmed-article:15126112 | pubmed:abstractText | The present study was undertaken to investigate the effects of bone morphogenetic protein-7 (BMP-7), also named osteogenic protein-1 (OP-1), on the progression of a striatal 6-hydroxydopamine (6-OHDA) lesion. BMP-7, a member of the transforming growth factor-beta (TGF-beta) superfamily of proteins, has been shown to have protective effects in other animal models of neuronal damage. In this study, male Fischer 344 rats received striatal 6-OHDA lesions followed 1 week later by an intraventricular dose of BMP-7. No significant effect of BMP-7 treatment on spontaneous locomotor activity was observed, however BMP-7 significantly increased the density of tyrosine hydroxylase (TH) immunoreactivity (TH-ir) in the substantia nigra (SN) pars compacta, in the lesioned hemisphere [31.7+/-5.2 (optical density (O.D.) arbitrary units) control vs. 50.2+/-4.3 O.D. BMP-7-treated; p<0.05]. Interestingly, BMP-7 significantly increased TH-ir in the SN of the non-lesioned hemisphere (pars reticulata: 14.8+/-1.19 O.D. control vs. 36+/-2.6 O.D. BMP-7-treated, p<0.05; pars compacta: 29.0+/-4.9 O.D. control vs. 64.4+/-6.9 O.D. BMP-7-treated, p<0.001). A significant increase in DA concentration in the contralateral, non-lesioned hemisphere was also noted (113.2 ng/g control vs. 198.2 ng/g BMP-7-treated, p<0.01). In contrast to other intraventricularly administered neurotrophic factors, BMP-7 was not associated with an increase in the sensitivity to pain. These results suggest that BMP-7 is able to act as a dopaminotrophic agent without unwanted side effects and as such may be a useful pharmacological tool in the treatment of Parkinson's disease in humans. | lld:pubmed |
| pubmed-article:15126112 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15126112 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126112 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15126112 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15126112 | pubmed:issn | 0006-8993 | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:GerhardtGreg... | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:BickfordPaula... | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:DavidDanielD | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:HudsonJohn... | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:KaplanPaul... | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:ZuchChristina... | lld:pubmed |
| pubmed-article:15126112 | pubmed:author | pubmed-author:UjhelyiLiviaL | lld:pubmed |
| pubmed-article:15126112 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15126112 | pubmed:day | 4 | lld:pubmed |
| pubmed-article:15126112 | pubmed:volume | 1010 | lld:pubmed |
| pubmed-article:15126112 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15126112 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15126112 | pubmed:pagination | 10-6 | lld:pubmed |
| pubmed-article:15126112 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:meshHeading | pubmed-meshheading:15126112... | lld:pubmed |
| pubmed-article:15126112 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15126112 | pubmed:articleTitle | Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion. | lld:pubmed |
| pubmed-article:15126112 | pubmed:affiliation | Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO, USA. | lld:pubmed |
| pubmed-article:15126112 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15126112 | lld:pubmed |
